Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
JANSSEN NZ LIMITED,Daratumumab subcutaneous,"Multiple myeloma, received one prior line of myeloma therapy (1PL).",Daratumumab subcutaneous (DarzalexÂ® SC),Options for investment,Hospital,Oncology Agents and Immunosuppressants
